New York Blood Center, Inc.

New York Blood Center, Inc., doing business as New York Blood Center Enterprises, is a non-profit manufacturer of blood products, blood components, and transfusion services that operates as a prime contractor delivering blood bank supplies to the Department of Veterans Affairs across multiple Veterans Integrated Service Networks and as a federal grant recipient conducting biomedical and infectious-disease research through the National Institutes of Health.

The organization is a tax-exempt non-profit corporation headquartered in Rye, New York, classified under NAICS 325411 (Blood and Organ Banks), and competes on a full-and-open basis without set-aside designations. New York Blood Center holds a parent position within its corporate structure and operates subsidiaries under the same registered name. The organization has been registered in SAM since 1998 and is one of the largest independent community-based blood centers in the United States, serving hospitals across New York, New Jersey, and multiple other states.

Customer concentration is heavily skewed toward the Department of Veterans Affairs. The VA Veterans Integrated Service Network 2 (VISN 2) accounts for 129 awards worth $113.1 million in combined potential value, representing the dominant federal customer by both award count and dollars. This concentration across a single VA network reflects the organization's primary federal contracting posture as a blood-supply vendor to the veterans healthcare system. The Health Resources and Services Administration (HRSA) ranks second with 3 awards carrying $35.8 million in combined potential value, followed by the Department of the Navy, the CDC, and the National Institute of Allergy and Infectious Diseases with smaller award volumes.

New York Blood Center holds a single-award indefinite delivery contract (IDC 36C24225D0050) with VA VISN 2 valued at $49.3 million through September 2029, from which 10 task orders were issued carrying $2.9 million in combined potential value. Additional IDCs support delivery-order activity: IDC VA24315D0030 has generated 49 task orders ($6.8 million), and IDC 36C24220D0023 has generated 30 task orders ($6.3 million). These vehicles structure the vendor's primary federal revenue stream around firm fixed-price delivery orders for blood products, blood components, and transfusion services to VA medical centers in the Northeast and Midwest regions. Recent Option Year 1 exercises issued in October 2025 against the VISN 2 IDC include orders ranging from $34,351.50 to $650,000, with completion dates of September 30, 2025, or September 30, 2026.

Federal grant activity spans research in hematology, infectious disease, and vaccine development. New York Blood Center is a prime recipient on Project Grants from the National Heart, Lung, and Blood Institute (NHLBI) including a $703,389 award (CFDA 93.837, Cardiovascular Diseases Research) for research on sex dimorphism in bone marrow niche and hematopoietic stem cell transplantation (award date July 15, 2026, period through April 30, 2030) and a $485,131 grant from the National Institute of Mental Health (CFDA 93.242, Mental Health Research Grants) for research on social networks and HIV testing and PrEP care among young Latin American gay, bisexual, and other men who have sex with men (award date September 22, 2025, completion September 21, 2027). The NHLBI has also funded grants addressing transfusion-driven hyperhemolysis in sickle cell disease, erythroblastic island macrophages in erythropoiesis, radiation countermeasures with sex-dependent responses, and accessory cells for improving hematopoietic stem cell transplantation homing and engraftment. The National Institute of Allergy and Infectious Diseases (NIAID) has funded research on babesiosis, vaccine responses in transgender women, and filarial worm drug discovery. All grants are Project Grants (assistance type) with performance in New York, New York.

Sub-award activity encompasses federal contract work and grant participation under prime contractors and grantee institutions. New York Blood Center serves as a subcontractor to Vitalant on the TTIMS LRCC (Transfusion Transmissible Infections Monitoring System Local Reference Center Capability) project, providing biostatistical and analytical support for HIV, HCV, HBV, and syphilis surveillance among blood donors (sub-awards dated December 29, 2023, and February 11, 2025). The organization is a Clinical Research Site under The Trustees of Columbia University in the City of New York for HIV vaccine and PrEP trials under the HIV Vaccine Trials Network (HVTN) and HIV Prevention Trials Network (HPTN), implementing protocols including HVTN 137, 144, 302, 303, and 304 (sub-awards dated November 11, 2024, and August 8, 2024). Grant sub-awards to NYBC from Washington University and Columbia University support filarial worm drug discovery and development (Onchocerca volvulus and Brugia species assays) and cord blood hematopoietic stem cell research via the National Cord Blood Program, which houses over 65,000 cord blood units. A sub-award from The Children's Hospital of Philadelphia (dated July 18, 2024, and August 11, 2026) funds red cell phenotyping, DNA testing for HEA and RHD/RHCE alleles, and biobanking to support transfusion research in pediatric patients with sickle cell disease.

Activity trajectory shows growth from 2022 through 2024 (10 to 19 awards annually) with a decline in 2025 and 2026 (16 and 2 awards respectively), though the latter years reflect partial-year capture. Recompete exposure in the next twenty-four months totals 10 awards with combined potential value of $12.3 million. The vendor's footprint is concentrated in blood-supply delivery to the VA (95% prime awards) and increasingly in federal biomedical research funding, particularly from NHLBI and NIAID, reflecting the organization's dual business model as both a clinical blood-supply vendor and a research institution operating the Lindsley F. Kimball Research Institute.